Stay updated on Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial

Sign up to get notified when there's something new on the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.0%
    Check dated 2025-04-30T16:51:06.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page has undergone significant changes, including the removal of detailed descriptions of a study on Dolutegravir (DTG) and the addition of a new registry identifier and revision number. The core content regarding the study's purpose and methodology has been largely deleted.
    Difference
    28%
    Check dated 2025-04-16T12:34:35.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.0%
    Check dated 2025-04-09T05:35:27.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.0%
    Check dated 2025-04-01T22:38:52.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The page has added helpful links related to adverse event reporting from the National Institute of Allergy and Infectious Diseases, while a notice about heavy traffic affecting NLM-NCBI services has been removed.
    Difference
    2%
    Check dated 2025-03-03T23:05:46.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.6%
    Check dated 2025-02-10T16:09:21.000Z thumbnail image

Stay in the know with updates to Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page.